Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02952573 | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back… | Phase 2 | terminated | Nov 2, 2016 | University Health Network, Toronto | Low patient accrual | Enrollment / accrual |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple… | Phase 1 | withdrawn | Apr 21, 2020 | Medical College of Wisconsin | Terminated for lack of funding. | Funding |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating…(NYSCT MM) | Phase 1 | withdrawn | Apr 24, 2018 | Jonsson Comprehensive Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes… | Phase 2 | withdrawn | Jun 19, 2020 | National Cancer Institute (NCI) | zero accrual | Enrollment / accrual |
| NCT03145870 | Prevalence of Asymptomatic Thrombosis in Multiple Myeloma | N/A | withdrawn | May 9, 2017 | Centre Hospitalier Universitaire, Amiens | investigator choice | Investigator |
| NCT03983486 | Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple…(CIF-PM) | — | withdrawn | Jun 12, 2019 | Centre Hospitalier Universitaire, Amiens | technical problem | Other (stated, no rule matched) |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With… | Phase 1 / Phase 2 | terminated | Apr 16, 2013 | Amgen | Enrollment halted during phase 2 to reformulate the investigational product | Enrollment / accrual |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post-… | Phase 2 | withdrawn | Dec 28, 2016 | University of Arkansas | Withdrawal of study support | Other (stated, no rule matched) |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | Phase 1 / Phase 2 | terminated | Sep 29, 2009 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | Ajai Chari | Low enrollment | Enrollment / accrual |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | terminated | Mar 17, 2006 | Masonic Cancer Center, University of Minnesota | IRB Study Closure | Other (stated, no rule matched) |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Aug 30, 2017 | Cogent Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From…(DARALLO) | Phase 2 | withdrawn | Jul 18, 2019 | Assistance Publique - Hôpitaux de Paris | Promotor decision | Other (stated, no rule matched) |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in… | Phase 1 / Phase 2 | terminated | Apr 29, 2016 | BioInvent International AB | Full clinical hold from FDA | Other (stated, no rule matched) |
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid)…(RID) | Phase 1 | terminated | Dec 5, 2012 | Yale University | The study was terminated due to withdrawal of institutional support, Phase II never began. | Other (stated, no rule matched) |
| NCT02784483 | Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic… | Phase 1 | terminated | May 27, 2016 | Yale University | Based on FDA requirements | Other (stated, no rule matched) |
| NCT02928029 | Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Oct 7, 2016 | Bayer | Due to the changes of standard of care and the slow recruitment of participants. | Enrollment / accrual |
| NCT01438177 | Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory… | Phase 2 | terminated | Sep 21, 2011 | NYU Langone Health | PI left institution. | Investigator |
| NCT03328936 | Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | Phase 2 | withdrawn | Nov 1, 2017 | Ohio State University Comprehensive Cancer Center | Sponsor decision | Sponsor / business decision |
| NCT03173430 | Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell… | Early Phase 1 | terminated | Jun 1, 2017 | Abramson Cancer Center at Penn Medicine | PI decided to close study due to slow accrual. | Enrollment / accrual |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple…(SMR-3184) | Phase 1 / Phase 2 | terminated | Jun 23, 2017 | Allarity Therapeutics | The study was terminated early due to sponsors decision | Other (stated, no rule matched) |
| NCT04243109 | Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients…(POCODEX) | Phase 2 | terminated | Jan 28, 2020 | Maimónides Biomedical Research Institute of Córdoba | Low recruitment rate. Lack of interest of the sponsor. | Enrollment / accrual |
| NCT02773550 | Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in…(Velcadito) | Phase 4 | terminated | May 16, 2016 | Basque Health Service | Low recruiment. | Other (stated, no rule matched) |
| NCT03608501 | A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive…(IDEALL) | Phase 2 | withdrawn | Aug 1, 2018 | Takeda | Business decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT00973804 | Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched… | Phase 1 | terminated | Sep 9, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01571726 | Imaging Studies and the Development of Multiple Myeloma | Phase 2 | withdrawn | Apr 5, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01660997 | MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma | Phase 2 | withdrawn | Aug 9, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01647165 | Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for… | Phase 2 | withdrawn | Jul 20, 2012 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02682953 | Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers | Phase 2 | withdrawn | Feb 17, 2016 | University of Maryland, Baltimore | subject recruitment not feasible due to standard care changes | Enrollment / accrual |
| NCT01239368 | Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma | Phase 1 / Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | Terminated due to insufficient accrual. | Enrollment / accrual |
| NCT02112045 | A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple… | Phase 2 | terminated | Apr 11, 2014 | Washington University School of Medicine | Terminated due to results of interim analysis | Efficacy / futility |
| NCT00765102 | Trial of Romidepsin and Bortezomib for Multiple Myeloma | Phase 2 | terminated | Oct 2, 2008 | Celgene | There was a change in the Sponsor's research strategy; safety concerns were not a factor. | Safety / toxicity |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With… | Phase 1 / Phase 2 | terminated | Sep 14, 2015 | Pharmacyclics LLC. | After completing Phase 1, the Sponsor elected not to move forward with Phase 2. | Other (stated, no rule matched) |
| NCT01248455 | A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma | Phase 2 | terminated | Nov 25, 2010 | National Cancer Institute (NCI) | Lack of patients meeting the defined primary obj. (50% decline in M-protein). | Other (stated, no rule matched) |
| NCT01772719 | Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and… | N/A | terminated | Jan 21, 2013 | University of Louisville | Principal Investigator left institution-study not continued | Investigator |
| NCT02579824 | Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in… | Phase 1 | terminated | Oct 20, 2015 | M.D. Anderson Cancer Center | stopped prematurely | Other (stated, no rule matched) |
| NCT00109109 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced… | Phase 1 | terminated | Apr 25, 2005 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT03952832 | Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma | Phase 2 | withdrawn | May 16, 2019 | City of Hope Medical Center | Budget issues | Funding |
| NCT02289222 | 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in… | Phase 1 / Phase 2 | terminated | Nov 13, 2014 | Ashraf Badros | Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the… | Other (stated, no rule matched) |
| NCT01783522 | Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving… | Phase 2 | terminated | Feb 5, 2013 | Beth Faiman | Research Cancelled | Other (stated, no rule matched) |
| NCT02043860 | Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for…(BMT-02) | Phase 1 | terminated | Jan 23, 2014 | University of Illinois at Chicago | low accrual | Enrollment / accrual |
| NCT03379584 | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma | Phase 1 | terminated | Dec 20, 2017 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT03785184 | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly… | Phase 2 | withdrawn | Dec 24, 2018 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03657420 | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and… | Phase 1 | withdrawn | Sep 5, 2018 | Massachusetts General Hospital | Funding withdrawn by sponsor | Funding |
| NCT02954796 | A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 3, 2016 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 17, 2020source: clinicaltrials